{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:25:42Z","timestamp":1764433542146,"version":"3.44.0"},"reference-count":18,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,11,29]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>A man in his late 70s, retired and independent, generally fit and well with a history of normal cognitive function baseline presented with liver abscess and acute kidney injury. He received meropenem 1 g three times a day for 15 days then subsequently changed to ertapenem 1 g one time a day in preparation for outpatient antibiotic treatment. After 2 days of starting ertapenem, the patient developed night-time delirium, decreased orientation and insomnia, loss of appetite, jerking and hallucination. Investigations have been done to investigate the cause of acute delirium, including lumbar puncture, CT brain, MRI brain, repeat CT abdomen and pelvis to monitor the liver abscess, and electroencephalogram but results were all unremarkable. Medication history during admission was reviewed and discontinued one by one the medications that were suspected to have caused the encephalopathy. Two days following the discontinuation of ertapenem, the patient\u2019s symptoms improved with a rapid return to his baseline and without neurological deficit.<\/jats:p>","DOI":"10.1136\/bcr-2023-256876","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:18:05Z","timestamp":1704845885000},"page":"e256876","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Ertapenem-induced encephalopathy in a patient with liver abscess and acute kidney injury"],"prefix":"10.1136","volume":"17","author":[{"given":"Shahid","family":"Farooq","sequence":"first","affiliation":[{"name":"Acute and General Medicine, Causeway Hospital, Coleraine, UK"},{"name":"Acute and General Medicine, Causeway Hospital, Coleraine, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Acosta","sequence":"additional","affiliation":[{"name":"Acute and General Medicine, Causeway Hospital, Coleraine, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"2025082710071633000_17.1.e256876.1","doi-asserted-by":"crossref","DOI":"10.1007\/s40800-015-0021-5","article-title":"Status epilepticus and delirium associated with ertapenem in a very elderly patient with chronic kidney disease and silent ischaemic cerebrovascular disease","volume":"2","author":"Lin","year":"2015","journal-title":"Drug Saf Case Rep"},{"key":"2025082710071633000_17.1.e256876.2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.4.408"},{"key":"2025082710071633000_17.1.e256876.3","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.1.5"},{"key":"2025082710071633000_17.1.e256876.4","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-231875","article-title":"Ertapenem-induced encephalopathy BMJ case Rep","volume":"13","author":"Adams","year":"2020","journal-title":"BMJ Case Rep"},{"key":"2025082710071633000_17.1.e256876.5","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200022030-00003"},{"key":"2025082710071633000_17.1.e256876.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2019.07.001"},{"key":"2025082710071633000_17.1.e256876.7","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.2147\/IDR.S406852","article-title":"Ertapenem-induced neurotoxicity: a literature review of clinical characteristics and treatment outcomes","volume":"16","author":"Wang","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2025082710071633000_17.1.e256876.8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12882-022-02980-8","article-title":"Ertapenem-induced neurotoxicity in an end-stage renal disease patient on intermittent haemodialysis: a case report","volume":"23","author":"Shahar","year":"2022","journal-title":"BMC Nephrol"},{"key":"2025082710071633000_17.1.e256876.9","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"2025082710071633000_17.1.e256876.10","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006291839"},{"key":"2025082710071633000_17.1.e256876.11","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg375"},{"key":"2025082710071633000_17.1.e256876.12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11096-013-9812-x","article-title":"Delayedrecovery from ertapenem induced encephalopathy: case-reportand a possible mechanism","volume":"35","author":"Shea","year":"2013","journal-title":"Int J Clin Pharm"},{"key":"2025082710071633000_17.1.e256876.13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/00365540802375570","article-title":"Seizures associated with ertapenem use Inpatients with CNS disorders and renal Insuf\ufb01ciency","volume":"40","author":"Fica","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"2025082710071633000_17.1.e256876.14","doi-asserted-by":"crossref","unstructured":"Sutton SS , Jumper M , Cook S , et al . Ertapenem-induced encephalopathy in a patient with normal renal function. J Investig Med High Impact Case Rep 2017;5. doi:10.1177\/2324709616689376","DOI":"10.1177\/2324709616689376"},{"key":"2025082710071633000_17.1.e256876.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03991.x"},{"key":"2025082710071633000_17.1.e256876.16","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(88)90071-X"},{"key":"2025082710071633000_17.1.e256876.17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cmi.2014.08.003","article-title":"Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study","volume":"21","author":"Zusman","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2025082710071633000_17.1.e256876.18","doi-asserted-by":"crossref","unstructured":"Gavaghan V , Luu T , Adams J , et al . Clinical outcomes of ertapenem in patients with hypoalbuminemia. Open Forum Infect Dis 2022;9.(Supplement_2) doi:10.1093\/ofid\/ofac492.654","DOI":"10.1093\/ofid\/ofac492.654"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-256876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:07:22Z","timestamp":1756314442000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-256876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,3]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/bcr-2023-256876"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-256876","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}